Neurocrine reports positive 2-year pediatric CAH data
- Neurocrine Biosciences (NASDAQ:NBIX) reported two-year Phase 3 CAHtalyst study data showing improved growth and metabolic health for children treated with CRENESSITY.
- Children with advanced bone age saw a mean bone age reduction of 1.12 SDS and a 4.7 cm gain in predicted height.
- The company stated that the treatment enabled sustained glucocorticoid reductions, which improved insulin resistance and body mass index measurements.
Neurocrine Biosciences (NASDAQ:NBIX) presented two-year pediatric data for its CRENESSITY therapy at the ENDO 2026 medical conference.
This study evaluated children with classic congenital adrenal hyperplasia, a condition that often requires high-dose steroid treatment.
Caregivers surveyed in the study reported 100% overall satisfaction and high levels of optimism regarding their children's future health outcomes.
The company stated the treatment was well-tolerated with no new safety signals, and following the announcement, Neurocrine's share price was up at $121.45.
Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders to address significant gaps in patient care.
The company continues to advance its clinical pipeline through various late-stage trials targeting hormonal regulation and rare disease treatment.
